Suchergebnisse - "Kristeleit, Rebecca S"

PubPharm (33)

1

Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer : a multi-national observational study

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2023

von Morgan, R. | Clamp, A. | Barnes, B. | +23

2

Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma : The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Banerjee, S. | Giannone, G. | Clamp, A. | +17

ErratumIn: JAMA Oncol. 2023 Aug 1;9(8):1155. - PMID 37318796

3

Reply to C. Marchetti et al

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Monk, B. | Fujiwara, K. | O'Malley, D. | +5

CommentOn: J Clin Oncol. 2023 Feb 1;41(4):935-936. - PMID 36201722

4

Correction to : A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

enthalten in: British journal of cancer | 2023

von Curigliano, G. | Shapiro, G. | Kristeleit, R. | +16

ErratumFor: Br J Cancer. 2023 Jan;128(1):30-41. - PMID 36335217

5

Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer : final results from Study 10

enthalten in: British journal of cancer | 2023

von Kristeleit, R. | Drew, Y. | Oza, A. | +13

6

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

enthalten in: British journal of cancer | 2023

von Curigliano, G. | Shapiro, G. | Kristeleit, R. | +16

ErratumIn: Br J Cancer. 2023 Jan;128(2):400. - PMID 36697966

7

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Monk, B. | Parkinson, C. | Lim, M. | +36

CommentIn: J Clin Oncol. 2023 Feb 1;41(4):935-936. - PMID 36201722

8

A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45) : original reports

enthalten in: Journal of clinical oncology | June 6, 2022

von Monk, B. | Parkinson, C. | Lim, M. | +36

9

ATHENA (GOG-3020/ENGOT-ov45) : a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2021

von Monk, B. | Coleman, R. | Fujiwara, K. | +18

10

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

enthalten in: Gynecologic oncology | 2021

von Swisher, E. | Kristeleit, R. | Oza, A. | +19